Vera Therapeutics (VERA) Stock Analysis

What Vera Therapeutics does

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Key metrics

ETFs linked to VERA

Broad-market and Healthcare sector ETFs an investor holding Vera Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VERA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Vera Therapeutics?

Vera Therapeutics trades under the ticker VERA on NASDAQ.

Which exchange is VERA listed on?

VERA is listed on NASDAQ.

What sector does Vera Therapeutics operate in?

Vera Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VERA in a portfolio?

PortView shows VERA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.